These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26552957)

  • 41. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer.
    Rutter CE; Yao X; Mancini BR; Aminawung JA; Chagpar AB; Saglam O; Hofstatter EW; Abu-Khalaf M; Gross CP; Evans SB
    Clin Breast Cancer; 2016 Feb; 16(1):59-62. PubMed ID: 26483315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In response: Genomic profile of breast cancer.
    Seguí MA; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna S; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):395-7. PubMed ID: 25797142
    [No Abstract]   [Full Text] [Related]  

  • 43. Translation, please.
    Bleiweiss IJ; Raptis G
    Lancet Oncol; 2007 Dec; 8(12):1044-1045. PubMed ID: 18054869
    [No Abstract]   [Full Text] [Related]  

  • 44. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.
    Spears M; Yousif F; Lyttle N; Boutros PC; Munro AF; Twelves C; Pritchard KI; Levine MN; Shepherd L; Bartlett JM
    Oncotarget; 2015 Oct; 6(31):31693-701. PubMed ID: 26372731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Gene expression tests can avoid unnecessary chemotherapy].
    Schlenger R
    Med Monatsschr Pharm; 2015 Feb; 38(2):70-1. PubMed ID: 26376544
    [No Abstract]   [Full Text] [Related]  

  • 46. [Molecular signatures of breast cancer: What clinical utility?].
    Delaloge S; Saghatchian M; Ghouadni A; Fekih M; André F
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S102-5. PubMed ID: 26118866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
    Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
    Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 testing and correlation with efficacy of trastuzumab therapy.
    Konecny G; Slamon DJ
    Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
    [No Abstract]   [Full Text] [Related]  

  • 49. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
    Enewold L; Geiger AM; Zujewski J; Harlan LC
    Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.
    Steeg PS
    Clin Cancer Res; 2008 Jun; 14(12):3643-5. PubMed ID: 18559575
    [No Abstract]   [Full Text] [Related]  

  • 51. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
    PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
    MacDonald KV; Bombard Y; Deal K; Trudeau M; Leighl N; Marshall DA
    Eur J Cancer; 2016 Jul; 61():85-93. PubMed ID: 27155447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy of brain tumors in aduts].
    Roth P; Weller M
    Nervenarzt; 2015 Apr; 86(4):495-505; quiz 506-7. PubMed ID: 25783972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PARP inhibitors in cancer: moving beyond BRCA.
    Telli ML
    Lancet Oncol; 2011 Sep; 12(9):827-8. PubMed ID: 21862406
    [No Abstract]   [Full Text] [Related]  

  • 57. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
    Magbanua MJ; Wolf DM; Yau C; Davis SE; Crothers J; Au A; Haqq CM; Livasy C; Rugo HS; ; Esserman L; Park JW; van 't Veer LJ
    Breast Cancer Res; 2015 May; 17(1):73. PubMed ID: 26021444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
    Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.